Abstract：
BACKGROUND: Subjective cognitive decline (SCD) in amyloid-positive (Aβ+) individuals was proposed as a clinical indicator of Stage 2 in the Alzheimer\'s disease (AD) continuum, but this requires further validation across cultures, measures, and recruitment strategies.
METHODS: Eight hundred twenty-one participants from SILCODE and DELCODE cohorts, including normal controls (NC) and individuals with SCD recruited from the community or from memory clinics, underwent neuropsychological assessments over up to 6 years. Amyloid positivity was derived from positron emission tomography or plasma biomarkers. Global cognitive change was analyzed using linear mixed-effects models.
RESULTS: In the combined and stratified cohorts, Aβ+ participants with SCD showed steeper cognitive decline or diminished practice effects compared with NC or Aβ- participants with SCD. These findings were confirmed using different operationalizations of SCD and amyloid positivity, and across different SCD recruitment settings.
CONCLUSIONS: Aβ+ individuals with SCD in German and Chinese populations showed greater global cognitive decline and could be targeted for interventional trials.
CONCLUSIONS: SCD in amyloid-positive (Aβ+) participants predicts a steeper cognitive decline. This finding does not rely on specific SCD or amyloid operationalization. This finding is not specific to SCD patients recruited from memory clinics. This finding is valid in both German and Chinese populations. Aβ+ older adults with SCD could be a target population for interventional trials.
METHODS: Eight hundred twenty-one participants from SILCODE and DELCODE cohorts, including normal controls (NC) and individuals with SCD recruited from the community or from memory clinics, underwent neuropsychological assessments over up to 6 years. Amyloid positivity was derived from positron emission tomography or plasma biomarkers. Global cognitive change was analyzed using linear mixed-effects models.
RESULTS: In the combined and stratified cohorts, Aβ+ participants with SCD showed steeper cognitive decline or diminished practice effects compared with NC or Aβ- participants with SCD. These findings were confirmed using different operationalizations of SCD and amyloid positivity, and across different SCD recruitment settings.
CONCLUSIONS: Aβ+ individuals with SCD in German and Chinese populations showed greater global cognitive decline and could be targeted for interventional trials.
CONCLUSIONS: SCD in amyloid-positive (Aβ+) participants predicts a steeper cognitive decline. This finding does not rely on specific SCD or amyloid operationalization. This finding is not specific to SCD patients recruited from memory clinics. This finding is valid in both German and Chinese populations. Aβ+ older adults with SCD could be a target population for interventional trials.
摘要：
背景：淀粉样蛋白阳性（Aβ）个体的主观认知功能下降（SCD）被认为是阿尔茨海默病（AD）连续体2期的临床指标，但这需要跨文化的进一步验证，措施，和招聘策略。
方法：来自SILCODE和DELCODE队列的8121名参与者，包括正常对照（NC）和从社区或记忆诊所招募的SCD患者，接受了长达6年的神经心理学评估。淀粉样蛋白阳性来自正电子发射断层扫描或血浆生物标志物。使用线性混合效应模型分析了全球认知变化。
结果：在合并和分层的队列中，与患有SCD的NC或Aβ参与者相比，患有SCD的Aβ参与者显示出更陡的认知下降或实践效果减弱。使用SCD和淀粉样蛋白阳性的不同操作证实了这些发现，以及不同的SCD招募设置。
结论：德国和中国人群中的Aβ+SCD患者表现出更大的全球认知能力下降，可以作为干预试验的目标。
结论：淀粉样蛋白阳性（Aβ+）参与者的SCD预示着更严重的认知功能下降。该发现不依赖于特定的SCD或淀粉样蛋白操作。这一发现并非特定于从记忆诊所招募的SCD患者。这一发现在德国和中国人群中都是有效的。Aβ+患有SCD的老年人可能是介入试验的目标人群。
方法：来自SILCODE和DELCODE队列的8121名参与者，包括正常对照（NC）和从社区或记忆诊所招募的SCD患者，接受了长达6年的神经心理学评估。淀粉样蛋白阳性来自正电子发射断层扫描或血浆生物标志物。使用线性混合效应模型分析了全球认知变化。
结果：在合并和分层的队列中，与患有SCD的NC或Aβ参与者相比，患有SCD的Aβ参与者显示出更陡的认知下降或实践效果减弱。使用SCD和淀粉样蛋白阳性的不同操作证实了这些发现，以及不同的SCD招募设置。
结论：德国和中国人群中的Aβ+SCD患者表现出更大的全球认知能力下降，可以作为干预试验的目标。
结论：淀粉样蛋白阳性（Aβ+）参与者的SCD预示着更严重的认知功能下降。该发现不依赖于特定的SCD或淀粉样蛋白操作。这一发现并非特定于从记忆诊所招募的SCD患者。这一发现在德国和中国人群中都是有效的。Aβ+患有SCD的老年人可能是介入试验的目标人群。
